Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410221 | 0.92 | ADORA1 (0.57) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL411493 | 0.91 | ADORA1 (0.65) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL10118210 | 0.85 | ADORA1 (0.41) | ADORA1ADORA2A | |
| SCHEMBL947228 | 0.85 | ADORA1 (0.65) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL946659 | 0.83 | ADORA1 (0.62) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL12359397 | 0.83 | ADORA1 (0.68) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL410912 | 0.82 | ADORA1 (0.67) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| Hydrochloric Acid SCHEMBL947706 | 0.82 | ADORA1 (0.66) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL947600 | 0.81 | ADORA1 (0.68) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL1740127 | 0.80 | ADORA1 (0.55) | ADORA1ADORA2AADORA3ADORA2BPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393552-B1 | A CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9708292-B2 | Cyanopyrimidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.